2
Orphan Designations
0 approved, 2 designated
0
FDA Approvals
0
Active Trials
4
Rare Diseases
across 3 areas
0
News (30d)
Quiet
Tempest Therapeutics is a company with 2 orphan drug designations across 4 rare diseases. gene therapy candidates in 1 disease.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| classic familial adenomatous polyposis | selective dual antagonist of the human prostaglandin E2 (PGE2) receptors EP2 and EP4 | Des.TrialAppr. |
| familial adenomatous polyposis 3 | selective dual antagonist of the human prostaglandin E2 (PGE2) receptors EP2 and EP4 | Des.TrialAppr. |
| familial adenomatous polyposis 4 | selective dual antagonist of the human prostaglandin E2 (PGE2) receptors EP2 and EP4 | Des.TrialAppr. |
| hepatocellular carcinoma | PPARalpha inhibitor | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
1/4
candidate diseases
0
avg importance: 0
0
affecting portfolio